Pathological subclassification and EBV assessment by EBER ISH and immunohistochemistry for LMP1 and EBNA2 in AIDS-related lymphoma
| AIDS lymphoma subtype . | No. . | EBV-positive (%) EBER-ISH . | Immunophenotype . | ||
|---|---|---|---|---|---|
| Latency I [LMP1−EBNA− (% of EBV+)] . | Latency II [LMP1+EBNA2− (% of EBV+)] . | Latency III [LMP1+EBNA2+ (% of EBV+)] . | |||
| DLBCL non-GC | 48 | 27 (56%) | 10 (37%) | 8 (30%) | 8 (30%) |
| DLBCL GCB | 98 | 25 (25%) | 19 (76%) | 3 (12%) | 3 (12%) |
| DLBCL null | 13 | 4 (31%) | 1 (25%) | 3 (75%) | |
| BL | 19 | 10 (53%) | 9 (90%) | 1 (10%) | |
| PBL | 9 | 8 (89%) | 8 (100%) | ||
| PEL (solid variant) | 14 | 12 (86%) | 11 (92%) | 1 (8%) | |
| BCL-U | 4 | 3 (75%) | 3 (100%) | ||
| Polymorphic LPD | 7 | 5 (71%) | 1 (20%) | 1 (20%) | 3 (60%) |
| Total | 212 | 94 (44%) | 61 (65%) | 15 (16%) | 17 (18%) |
| AIDS lymphoma subtype . | No. . | EBV-positive (%) EBER-ISH . | Immunophenotype . | ||
|---|---|---|---|---|---|
| Latency I [LMP1−EBNA− (% of EBV+)] . | Latency II [LMP1+EBNA2− (% of EBV+)] . | Latency III [LMP1+EBNA2+ (% of EBV+)] . | |||
| DLBCL non-GC | 48 | 27 (56%) | 10 (37%) | 8 (30%) | 8 (30%) |
| DLBCL GCB | 98 | 25 (25%) | 19 (76%) | 3 (12%) | 3 (12%) |
| DLBCL null | 13 | 4 (31%) | 1 (25%) | 3 (75%) | |
| BL | 19 | 10 (53%) | 9 (90%) | 1 (10%) | |
| PBL | 9 | 8 (89%) | 8 (100%) | ||
| PEL (solid variant) | 14 | 12 (86%) | 11 (92%) | 1 (8%) | |
| BCL-U | 4 | 3 (75%) | 3 (100%) | ||
| Polymorphic LPD | 7 | 5 (71%) | 1 (20%) | 1 (20%) | 3 (60%) |
| Total | 212 | 94 (44%) | 61 (65%) | 15 (16%) | 17 (18%) |
These 212 cases were classified as latency I in EBER+ cases when no LMP1 or EBNA2 was expressed, as latency II when these were positive for LMP1 but negative for EBNA2, and as latency III where there was expression of both EBNA2 and LMP1. BCL-U, B-cell lymphoma, unclassifiable, with features of DLBCL and BL; DLBCL null, negative for CD10, BCL6 and MUM1; LPD, lymphoproliferative disorder; PEL, primary effusion lymphoma.